Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: A retrospective multicentric study
Schöffski, Patrick × Taron, M. Jimeno, J. Grosso, F. Sanfilipio, R. Casali, P.G. Le Cesne, A Jones, R.L. Blay, J.Y. Poveda, A. Maki, R.G. Nieto, A. Tercero, J.C Rosen, R. #
European Journal of Cancer vol:47 issue:7 pages:1006-1012
Aim: Trabectedin sensitivity is increased in cells with functional nucleotide excision DNA repair, whereas efficient homologous recombination repair leads to resistance. On this basis, a retrospective study of mRNA expression of BRCA1 (breast cancer susceptibility 1 gene), XPG (Xeroderma pigmentosum group G gene) and ERCC1 (excision-repair cross complementing group 1 gene) in tumour samples from sarcoma patients treated with trabectedin was conducted, to correlate DNA repair profiles with patient outcome.